Oral compositions containing zinc, stannous and fluoride ion sources

Patent metadata

Field	Value
Publication number	US-10154948-B2
Application number	US-201415319636-A
Country	US
Kind code	B2
Filing date	Jun 20, 2014
Priority date	Jun 20, 2014
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

An oral care composition containing a source of stannous ions, a source of fluoride ions and an insoluble source of zinc ions, such as zinc oxide. The composition contains an amount of citric acid sufficient to increase the level of soluble zinc ions.

First claim

What is claimed is:

1. An oral care composition comprising in a single phase:
(a) an orally acceptable vehicle;
(b) a source of fluoride ions;
(c) a source of stannous ions;
(d) an insoluble source of zinc ions;
(e) a buffering system comprising citric acid wherein the amount of citric acid is at least 1% by weight of the composition, and
wherein the composition has a total water content of less than 15% by weight, based on the weight of the composition.

2. The composition of claim 1 wherein the amount of citric acid is 1-3 wt. %, or 1.1-1.5 wt. % or 1.8-2.2 wt. %, based on the weight of the composition.

3. The composition of claim 1 wherein the amount of citric acid is 1-3 wt. % based on the weight of the composition.

4. The composition of claim 1 wherein the amount of citric acid is 1.1-1.5 wt. % based on the weight of the composition.

5. The composition of claim 1 wherein the amount of citric acid is 1.8-2.2 wt. % based on the weight of the composition.

6. The composition of claim 1 , wherein the insoluble source of zinc ions comprises zinc oxide, zinc phosphate, zinc pyrophosphate or a mixture thereof.

7. The composition of claim 1 wherein the source of fluoride ions and the source of stannous ions comprises stannous fluoride.

8. The composition of claim 1 comprising at least one polyphosphate salt selected from the group consisting of inorganic polyphosphate salts which have equal to or less than three phosphorous atoms.

9. The composition of claim 8 , wherein the at least one polyphosphate is selected from the group consisting of tetrasodium pyrophosphate, sodium tripolyphosphate, and mixtures thereof; wherein the total polyphosphate comprises from 1 to 10 wt % of the composition.

10. The composition of claim 1 wherein the buffering system comprises a mixture of citric acid and trisodium citrate.

11. The composition of claim 1 comprising polyvinylpyrrolidone, a gum, or a mixture thereof.

12. The composition of claim 1 comprising a modified cellulose such as carboxymethyl cellulose.

13. The composition of claim 1 further comprising at least one humectant selected from the group consisting of glycerin, polyethylene glycol, propylene glycol, and mixtures thereof.

14. The composition of claim 1 wherein the composition is a dentifrice comprising one or more of an abrasive, a surfactant, a foaming agent, a vitamin, a polymer, a whitening agent, an enzyme, a humectant, a thickener, an antimicrobial agent, a preservative, L-arginine, a flavoring, or a coloring agent.

15. The composition of claim 1 comprising:
(a) 1-3 wt. % citric acid;
(b) 0.5-10 wt % Trisodium citrate;
(c) 0.1-5 wt % Zinc oxide;
(d) 0.1-5 wt % Stannous fluoride;
(e) 10-50 wt % Glycerin;
(f) 1-25 wt. % Propylene glycol; optionally comprising one or more of:
(g) 0.1-12 wt % xanthan gum;
(h) 0.25-10 wt % polyvinylpyrrolidone (PVP);
(i) 0.2-1.5% wt. % carboxymethylcellulose (CMC);
(j) 5-60 wt % Silica (total);
(k) 0.1-10 wt % Tetrasodium Pyrophosphate (TSPP);
(l) 0-5 wt % Sodium acid pyrophosphate (SAPP);
(m) 0.1-10 wt % Sodium Tripolyphosphate (STPP);
(n) 0.1-10 wt % Sodium lauryl sulfate (SLS);
(o) 0.1-10 wt % Cocamidopropyl betaine.

16. The oral care composition of claim 15 comprising:
(a) 1.1-1.5 wt. % or 1.8-2.2 wt. % citric acid;
(b) 2-4 wt % Trisodium citrate;
(c) 0.5-2 wt % Zinc oxide;
(d) 0.1-2 wt % Stannous fluoride;
(e) 10-50 wt % Glycerin;
(f) 2-10 wt % Propylene glycol; optionally comprising one or more of:
(g) 0.1-0.5% wt % xanthan gum;
(h) 0.25-10 wt % polyvinylpyrrolidone (PVP);
(i) 0.3-0.9 wt. % carboxymethylcellulose (CMC);
(j) 10-40 wt % Silica (total);
(k) 1-4 wt % Tetrasodium Pyrophosphate (TSPP);
(l) 0.5-1.5 wt % Sodium acid pyrophosphate (SAPP);
(m) 1-4 wt % Sodium Tripolyphosphate (STPP);
(n) 1.2-2.5 wt % Sodium lauryl sulfate (SLS);
(o) 0.5-2 wt % Cocamidopropyl betaine.

17. The oral care composition of claim 16 comprising:
(a) 1.1-1.5 wt. % or 1.8-2.2 wt. % citric acid;
(b) 2.9-3.1 wt % Trisodium citrate;
(c) 0.9-1.1 wt % Zinc oxide;
(d) 0.4-0.6% wt % Stannous fluoride;
(e) 10-50 wt % Glycerin;
(f) 6-8 wt % Propylene glycol; optionally comprising one or more of:
(g) 0.275-0.325 wt % xanthan gum;
(h) 0.25-10 wt % polyvinylpyrrolidone (PVP);
(i) 0.65-0.75 wt. % carboxymethylcellulose (CMC);
(j) 22-26 wt % Silica (total);
(k) 1.75-2.25 wt % Tetrasodium Pyrophosphate (TSPP);
(l) 0.9-1.1 wt % Sodium acid pyrophosphate (SAPP);
(m) 2.75-3.25 wt % Sodium Tripolyphosphate (STPP);
(n) 1.5-1.75 wt % Sodium lauryl sulfate (SLS);
(o) 0.75 to 1.25 wt % Cocamidopropyl betaine.

18. A method of treating a disease or condition of the oral cavity comprising contacting an oral cavity surface of a patient in need thereof with the composition of claim 1 .

19. The method of claim 18 , wherein the disease or condition of the oral cavity is biofilm formation, plaque formation, oral inflammation or a combination thereof.

Assignees

• Colgate Palmolive Co

Inventors

• Vemishetti Kavita
• Fruge Linh
• Prencipe Michael

Classifications

• A61K8/21

  Fluorides; Derivatives thereof · CPC title

• A61K8/24

  Phosphorous; Compounds thereof · CPC title

• A61K8/27 Primary

  Zinc; Compounds thereof · CPC title

• A61Q11/00

  Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses · CPC title

• A61K8/365

  Hydroxycarboxylic acids; Ketocarboxylic acids · CPC title